AYMEN MOHAMMED (Division of Molecular Therapeutics and Formulations, School of Pharmacy, University of Nottingham), Naim Hage (Division of Molecular Therapeutics and Formulations, School of Pharmacy, University of Nottingham), Waleed Alharbi (Division of Molecular Therapeutics and Formulations, School of Pharmacy, University of Nottingham), Abdulaziz Alouffi (Division of Molecular Therapeutics and Formulations, School of Pharmacy,The University of Nottingham), Nora Francini (Division of Molecular Therapeutics and Formulations, School of Pharmacy, University of Nottingham), Vasiliki Paraskevopoulou (Division of Molecular Therapeutics and Formulations, School of Pharmacy, University of Nottingham), Paul Gellert (Pharmaceutical Development, AstraZeneca R&D, Charter Way, Macclesfield, Cheshire SK10 2NA), Ross Overman (Discovery Sciences, Innovative Medicines and Early Development, AstraZeneca R&D, Alderley Park, Cheshire SK10 4TG), Geoffrey Holdgate (Discovery Sciences, Innovative Medicines and Early Development, AstraZeneca R&D, Alderley Park, Cheshire SK10 4TG), Sebastiaan Winkler (Biomolecular Science and Medicinal Chemistry Division, School of Pharmacy, University of Nottingham), Snow Stolnik-Trenkic (Division of Molecular Therapeutics and Formulations, School of Pharmacy, University of Nottingham), Franco Falcone (Division of Molecular Therapeutics and Formulations, School of Pharmacy, University of Nottingham)